A detailed history of Octagon Capital Advisors LP transactions in Verona Pharma PLC stock. As of the latest transaction made, Octagon Capital Advisors LP holds 1,835,200 shares of VRNA stock, worth $82.7 Million. This represents 12.75% of its overall portfolio holdings.

Number of Shares
1,835,200
Previous 1,895,200 3.17%
Holding current value
$82.7 Million
Previous $27.4 Million 92.67%
% of portfolio
12.75%
Previous 6.33%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.46 - $30.16 $927,600 - $1.81 Million
-60,000 Reduced 3.17%
1,835,200 $52.8 Million
Q2 2024

Aug 14, 2024

SELL
$11.48 - $17.02 $5.44 Million - $8.06 Million
-473,800 Reduced 20.0%
1,895,200 $27.4 Million
Q4 2023

Feb 14, 2024

SELL
$11.94 - $20.47 $1.18 Million - $2.03 Million
-99,000 Reduced 4.01%
2,369,000 $47.1 Million
Q4 2022

Feb 14, 2023

BUY
$9.84 - $26.13 $24.3 Million - $64.5 Million
2,468,000 New
2,468,000 $64.5 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.75B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.